Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
(Thomson Reuters ONE) -
Basilea Pharmaceutica AG /
Basilea announces development of inhaled dosage form of its Gram-negative
antibiotic BAL30072 as part of European iABC program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC)
program to develop new antibiotic treatments for cystic fibrosis and
bronchiectasis
Basel, Switzerland, September 7, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
announced today that an inhaled formulation of its antibiotic BAL30072 will be
developed as part of a new Europe-wide program focusing on new antibiotics that
could improve the lives of patients with cystic fibrosis and bronchiectasis.
BAL30072 is an investigational monosulfactam antibiotic with in-vitro and in-
vivo activity against many clinically relevant multidrug-resistant Gram-negative
bacteria.
The iABC (inhaled Antibiotics in Bronchiectasis and Cystic fibrosis) consortium,
which includes world-leading lung specialists from across Europe, will develop
new inhaled antibiotics to manage chronic lung infection, the main cause of
disease and mortality in patients with cystic fibrosis and bronchiectasis.
The new drugs are being developed in response to an urgent need for new forms of
inhaled antibiotics. They are expected to improve patients' quality of life by
reducing lung infections and flare-ups, improving lung function, and overcoming
antibacterial resistance which frequently occurs in patients with these
conditions.
Prof. Achim Kaufhold, Basilea's Chief Medical Officer, stated: "We are pleased
to work with the iABC consortium within the European IMI, focusing on the high
medical need associated with resistant Gram-negative infections that affect
cystic fibrosis and bronchiectasis patients." He added: "The development of an
inhaled version of BAL30072 as a targeted treatment option for chronic lung
infections may provide a new treatment option for these patients. The project
will initially include pre-clinical development activities in preparation of
clinical phase 1 studies."
The five-year iABC program is part of the European New Drugs for Bad Bugs
(ND4BB) program and will also establish the first European patient register for
bronchiectasis, providing a platform to improve the quality of care for patients
across Europe as well as making it easier to develop and trial new drugs.
The iABC consortium, which is led by researchers from the School of Medicine,
Dentistry and Biomedical Sciences, and the School of Pharmacy at Queen's
University Belfast with EFPIA(*) partners Basilea and Novartis is funded by the
European Commission through the Innovative Medicines Initiative (IMI) and
through contributions by EFPIA companies. The total funding for BAL30072 related
work will be approximately EUR 11 million of which Basilea contributes about
half. The consortium involves researchers from 20 organizations in eight
countries across Europe.
About cystic fibrosis and bronchiectasis
Cystic fibrosis (CF) is a genetic disease that blocks a patient's lungs and
digestive system, affecting approximately 36,000 people in the European Union.
Chronic bacterial pulmonary infection leading to an irreversible decline in lung
structure and function is the main cause of mortality and morbidity in patients
with CF. Pseudomonas aeruginosa is the most frequently isolated pathogen,
chronically infecting up to 80% of adult patients. More than 95% of deaths in
patients with cystic fibrosis are due to respiratory failure, often as a result
of chronic lung infection.
Bronchiectasis (BE) is a group of diseases in which a person's airways become
damaged and scarred. In developed countries, BE affects from 4 per 100,000 young
adults to nearly 300 per 100,000 persons 75 years and older. In 2012 it was
calculated that 2.4 million of patients worldwide were affected by BE, and
estimated to grow to 3 million in 2020. Patients with BE suffer from similar
symptoms as patients with CF. Estimates suggest that the airways of almost all
patients with bronchiectasis are chronically infected with pathogenic bacteria.
More than 30% of the BE patients suffer from chronic Pseudomonas aeruginosa
infections.
About the iABC consortium
The iABC consortium involves researchers from Northern Ireland, Scotland,
England, Spain, Germany, France, Italy, Belgium, the Netherlands and
Switzerland.
Organisations involved in the iABC consortium are Queen's University Belfast,
Belfast Health and Social Care Trust, University Medical Center Utrecht,
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V., Hannover,
Rijksuniversiteit Groningen, Servicio Madrileño de Salud, Madrid, Universitair
Ziekenhuis Antwerpen, University of Dundee, Institut National de la Santé et de
la Recherche, Poitiers, Università degli Studi di Milano, Hospices Civils de
Lyon, Medizinische Hochschule Hannover, Universiteit Antwerpen, University of
Edinburgh, Royal Brompton and Harefield NHS Foundation Trust, Fundació Clínic
per a la Recerca Biomèdica, Barcelona, Papworth Hospital NHS Foundation Trust,
Erasmus Medical Center, Rotterdam, and the EFPIA companies Basilea Pharmaceutica
International Ltd., and Novartis Pharma AG, Basel.
About IMI, ND4BB and EFPIA
In November 2011, the European Commission launched its Action Plan against the
rising threat from Antimicrobial Resistance, and called for "unprecedented
collaborative research and development efforts to bring new antibiotics to
patients." The New Drugs for Bad Bugs (ND4BB) program was launched within the
Innovative Medicines Initiative (IMI) in direct response to this call. IMI is a
joint undertaking between the European Union and the European Federation of
Pharmaceutical Industries and Associations (EFPIA); it constitutes Europe's
largest public-private initiative aiming to accelerate the development of better
and safer medicines for patients. More information: www.imi.europa.eu.
The EFPIA brings together 33 European national pharmaceutical industry
associations as well as 40 leading companies undertaking research, development
and the manufacture in Europe of medicinal products for human use. More
information: www.efpia.eu.
About Basilea
Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment options
in the therapeutic areas of bacterial infections, fungal infections and cancer.
The company uses the integrated research, development and commercial operations
of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop
and commercialize innovative pharmaceutical products to meet the medical needs
of patients with serious and potentially life-threatening conditions. Basilea
Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX
Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's
website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition, performance
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any forward-
looking statements contained herein as a result of new information, future
events or otherwise.
For further information, please contact:
+-----------------------------+--------------------------------+
| Media Relations | Investor Relations |
+-----------------------------+--------------------------------+
| Peer Nils Schröder, PhD | Barbara Zink, PhD, MBA |
| Head Public Relations & | Head Corporate Development |
| Corporate Communications | |
| +41 61 606 1102 | +41 61 606 1233 |
| media_relations(at)basilea.com | investor_relations(at)basilea.com |
+-----------------------------+--------------------------------+
This press release can be downloaded from www.basilea.com.
References
* European Federation of Pharmaceutical Industries and Associations
Press release (PDF):
http://hugin.info/134390/R/1949998/708837.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via GlobeNewswire
[HUG#1949998]
Unternehmensinformation / Kurzprofil:
Datum: 07.09.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 418251
Anzahl Zeichen: 10049
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 276 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program"
steht unter der journalistisch-redaktionellen Verantwortung von
Basilea Pharmaceutica AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
